Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bivalent Type 1 & 3 Oral Poliomyelitis Vaccines
- Development stage
- Unknown
- Lead developer
- Bio Farma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
**Bivalent Type 1 & 3 Oral Poliomyelitis Vaccines** is Bio Farma's live-attenuated oral poliovirus vaccine for active prevention of poliomyelitis caused by poliovirus types 1 and 3. Each 0.1 mL oral dose comprises two drops containing Sabin-strain poliovirus types 1 and 3. The vaccine is supplied as a multidose oral suspension and is intended for direct oral administration; it has been evaluated in Indonesian infants, including concomitant administration with Pentabio and inactivated poliovirus vaccine. ([biofarma.co.id](https://www.biofarma.co.id/en/our-product/detail/bivalen-type-1-3-oral-poliomyelitis-vaccines))
- Other names
- Bivalent Oral Polio Vaccine Bio FarmaBivalent Type 1 & 3 Oral Poliomyelitis VaccinesVaksin Poliomyelitis Oral Bivalen Tipe 1 & 3bOPV Bio Farma
Beyond the preview
Go deeper on Bivalent Type 1 & 3 Oral Poliomyelitis Vaccines.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bivalent Type 1 & 3 Oral Poliomyelitis Vaccines.